Share on PinterestThe delta variant has led to a COVID-19 surge in the U.S. Martinez Velez/Europa Press via Getty ImagesCOVID-19 cases are rising in t
- COVID-19 cases are rising in the United States, and the delta variant has been identified in all 50 states.
- The delta variant is now responsible for more than 58 percent of new coronavirus infections in the United States, and there’s been an increase in hospitalizations.
- Of people hospitalized, a majority are either unvaccinated or partially vaccinated.
- Even though vaccines offer different ranges of protection, experts say getting fully vaccinated is crucial.
The United States is now dealing with the delta variant of the coronavirus, a highly contagious variant that was first identified in India in December.
As with previous variants, the delta variant has spread to many countries across the world, including, most notably, the United Kingdom, where it’s now responsible for around 99 percent of new cases.
The United States first announced that it had diagnosed a case with the delta variant in March this year. It’s now the dominating variant nationwide, making up more than half of all new infections in the country.
Confirmed infections with the delta variant have also been doubling since June. The average is more than 24,000 a day, according to data from the Centers for Disease Control and Prevention (CDC).
This rise has been attributed, in part, to the delta variant being an estimated
Additionally, areas with low vaccination rates are more likely to see a surge in infections.
Low vaccine uptake driving up infections
“The unvaccinated population is at high risk for infection. If this variant continues to move quickly, especially in areas of low vaccination rates, the U.S. could see a surge in SARS-CoV-2 infection,” said Dr. Miriam Smith, chief of infectious disease at Long Island Jewish Forest Hills Teaching Hospital in Queens, New York City.
In a press briefing, she said preliminary data suggested that 99.5 percent of the people who died from COVID-19 since January were unvaccinated.
“We know that the delta variant… is currently surging in pockets of the country with low vaccination rates,” she said.
In Missouri, which has a vaccination rate of 40.26 percent, confirmed coronavirus infections have almost doubled in the past 2 weeks.
In contrast, Vermont reported only 32 cases on July 12 and currently has one of the highest vaccination rates in the country at 67.70 percent.
This echoes findings from
“We also know that our authorized vaccines prevent severe disease, hospitalization, and death from the delta variant,” Walensky said.
Dr. Theodore Strange, the interim chair of medicine at Staten Island University Hospital in New York, said the data supports this.
“The safety and efficacy of the current vaccines are very clear. These three vaccines do work to prevent disease and the spread of disease, and they are as safe as any other vaccines that have been in use. Although some side effects have been reported, these issues are rare and treatable,” he told Healthline.
All three vaccines are proven to be effective in varying degrees against the original variant of the coronavirus, SARS-CoV-2, that causes COVID-19.
However, since the delta variant emerged, scientists have been trying to establish whether these vaccines are as effective against it.
We broke down what the current data says. But new research could mean this data will change over time.
The Pfizer-BioNTech COVID-19 vaccine
Due to limited research so far, trying to determine the effectiveness of each vaccine against the delta variant remains a challenge. However, there have been promising results from multiple studies.
Study 1 and real-life data
According to an analysis carried out by Public Health England, two doses of the Pfizer-BioNTech vaccine appeared to be about 88 percent effective against symptomatic disease and 96 percent effective against hospitalization with the delta variant.
The same study suggested that the vaccine was approximately 80 percent effective against preventing infection from the delta variant. Scientists came to this conclusion after analyzing 14,019 people with an infection, 166 of whom were hospitalized, in England.
Vaccines had a protective effect against infections with delta and hospital cases were milder, the study found.
Public Health England also shared real-world data in May that solidified the importance of having a second dose of COVID-19 vaccine. The analysis suggested that a single dose of the Pfizer-BioNTech vaccine offered only about 33 percent protection against symptomatic disease.
This was a reduction from the previous 50 percent effectiveness estimated against the alpha variant.
The study also found that the Pfizer-BioNTech vaccine was 88 percent effective against the delta variant 2 weeks after the second dose.
However, researchers also reported that people who had received two doses of a vaccine had significantly more protection against infection with the delta variant, with researchers estimating a level of 95 percent effectiveness.
The study also found that the delta variant was less sensitive to “sera from naturally immunized individuals,” meaning people who had a prior infection may not be protected against reinfection with the delta variant.
A study in Canada, meanwhile, found that two doses of a COVID-19 vaccine worked just as well against the delta variant as it did with alpha. It has not yet been peer reviewed.
The study suggested the Pfizer-BioNTech vaccine was around 87 percent effective 14 days after two doses.
A study in Israel was more of an outlier and found that the Pfizer-BioNTech vaccine did not offer as high protection as previously estimated. The study suggested the vaccine was about 64 percent effective against preventing infection with the delta variant and 64 percent effective against symptomatic illness after two doses.
But scientists have pointed out that the full data has not yet been released, and it may have included asymptomatic infections picked up by Israel’s surveillance program.
Estimated effectiveness of Pfizer-BioNTech vaccine
Anywhere from 64 to 96 percent effective against the delta variant with two doses.
A third dose?
Pfizer and BioNTech say they’re now in the process of developing a third dose of their COVID-19 vaccine that will act as a booster against the delta variant. The companies said new data from the Israeli Ministry of Health, which showed that the vaccine’s effectiveness declines after 6 months, spurred them to launch the research.
Clinical trials for the booster vaccine could begin as early as August.
“Pfizer-BioNTech is seeking FDA approval for a booster to address waning antibody 6 months following full immunization, with particular concerns for protection against new variants,” Smith said.
However, Smith told Healthline that the currently available vaccines have been effective in preventing severe disease, including those identified with current variants of concern.
“Further, the CDC has not recommended a booster following any vaccine against SARS-CoV-2, as current data are limited,” she added.
The Moderna COVID-19 vaccine
There are multiple lab studies that suggest the Moderna COVID-19 vaccine works against the delta variant. And similar to the Pfizer-BioNTech vaccine, Moderna is also testing whether a third dose is beneficial.
A lab study on the Moderna vaccine showed that the vaccine was capable of providing protection against the delta variant and other variants tested, even though it was much more reduced compared with the alpha variant.
But the most interesting finding was that the vaccine was far more effective in producing antibodies against delta than it was against beta, according to the data, which has not yet been peer reviewed.
“As we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. [T]hese new data are encouraging and reinforce our belief that the Moderna COVID-19 vaccine should remain protective against newly detected variants,” Stéphane Bancel, CEO of Moderna, said in a statement.
No clear level of effectiveness was mentioned.
The same Canadian study that found the Pfizer-BioNTech vaccine to be 87 percent effective suggested that the Moderna vaccine was 72 percent effective against the delta variant after one dose.
There wasn’t enough data to calculate protection after two doses for Moderna. It’s also important to point out that the study has not yet been peer reviewed.
The findings, however, indicate that even a single dose of the Moderna or Pfizer-BioNTech vaccines provides “good to excellent” protection against symptomatic infection as well as severe illness. Two doses were also found likely to provide even higher protection.
Estimated effectiveness of Moderna COVID-19 vaccine
One study estimates 72 percent effectiveness from one dose. Other studies suggest it may offer similar protection as the Pfizer-BioNTech vaccine.
The Johnson & Johnson COVID-19 vaccine
There’s little data that shows how effective the Johnson & Johnson (J&J) single-shot COVID-19 vaccine is at protecting against the delta variant. The company is also reportedly researching whether a second shot would boost immunity against the variants.
A recent clinical trial suggested that the vaccine was 85 percent effective against severe disease and demonstrated “strong, persistent” protection against hospitalization and death.
It also showed that the J&J vaccine prompted “neutralizing antibody activity,” which stops the virus from infecting healthy cells, against the delta variant at a higher level than it did for the beta variant.
The Pfizer-BioNTech and AstraZeneca vaccines had shown a decline in effectiveness against the latter in another study.
Interim results from a study involving 20 people has shown that the J&J vaccine neutralized the delta variant within 29 days of the first shot, and protection improved over time.
“Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Dr. Mathai Mammen, the global head of Janssen Research & Development at Johnson & Johnson, in a July 1 press release.
Estimated effectiveness of J&J COVID-19 vaccine
More studies are needed to reach a definitive answer.
The World Health Organization (WHO) has said
But it has also acknowledged that the vaccines may offer less protection against milder, symptomatic illness caused by delta, though studies still suggest that people fully vaccinated “retain significant protection against the delta variant.”
Receiving the full regimen of two doses of a mRNA COVID-19 vaccine, such as Pfizer-BioNTech or Moderna vaccines, has also shown to be much more effective against the delta variant.
“The bottom line is that the vaccination program with any of the current vaccines available is the only way to break the cycle of spread by not allowing the virus to infect unvaccinated hosts and then mutate into variants such as delta. These vaccines are safe and with a high degree of efficacy to prevent further morbidities and mortalities,” Strange said.
Prof. Tim Spector, an epidemiologist from King’s College London, told Healthline that it is now time for the United States to take lessons from the United Kingdom in dealing with this new variant.
“[They] should start spreading the word about the new symptoms. [D]o not get too relaxed when you get your vaccine either, especially if you are in a high-risk area,” he said.
“Your risk may be an eighth of what it was [after getting vaccinated] but still a considerable number of people will be infected,” he added, highlighting the importance of physical distancing and wearing masks in crowded, unventilated places.